Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen healthcare supply chains, with a reported $3 billion investment commitment. The company's shares recently traded around $179.39, with a market cap near $49.4 billion. This partnership aims to enhance U.S. medical product production and innovation, but Barclays expects BDX to underperform its peers in the near term.
BDX shares trade at USD 180.43 on Pluang as of Oct 07, 2026 22:51 WIB, showing a slight 0.07% increase in the last day. The stock's market cap stands at $49.11 billion, closely matching the article's figure, while its dividend yield is 2.33%. This trading data provides a snapshot of BDX's market position amid Barclays' cautious rating and the company's U.S. manufacturing partnership.
BD (Becton, Dickinson and Company) celebrated 65 years of manufacturing syringes in Canaan, Connecticut, where it produces over 2 billion syringes annually. The site, which started in 1961 with 8 employees, now employs over 500 people and has expande...
BD (Becton, Dickinson and Company) has appointed Ferass Abuzaina as the worldwide president of its Surgery business unit, effective immediately. Abuzaina will lead the global strategic, operational, and commercial efforts of the Surgery division from...
BD (Becton, Dickinson and Company) announced a major partnership with the U.S. government to invest $19 billion in expanding domestic manufacturing of essential medical consumables. This initiative aims to strengthen healthcare supply chains, increas...
